U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07528027) titled 'Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity' on April 07.
Brief Summary: The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Hypertension With Overweight or Obesity
Intervention:
DRUG: HRS-7535
HRS-7535
DRUG: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shandong Suncadia Medicine Co., Ltd.
Disclaimer: Curated by HT Syndication....